Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

wherein

X is CH_2, O or S;

R represents 1-3 substituents independently selected from H, (C_{1-4})alkyl, (C_{1-4})alkyloxy and halogen;

R_1 is (C_{5-8})cycloalkyl;

R_2 is H or (C_{1-4})alkyl;

R_3, R_3', R_4, R_4', R_5, R_5' and R_6' are independently hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen;

R_6 is hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen; or

R_6 forms together with R_7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

~~R_7 forms together with R_6 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S~~; or

R_7 is H, (C_{1-4})alkyl or (C_{3-5})cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C_{1-4})alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (original) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R_1 is cyclopentyl or cyclohexyl.

3. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein X is CH_2 or O.

4. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

5. (Cancelled)

6. (Previously Presented) A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)-carbonyl]piperazine derivative of claim 1 together with a pharmaceutically acceptable carrier therefor.

7. (Cancelled)

8. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein X is CH_2 or O.

9. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

10. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

11. (Previously Presented) A method of treating pain in a patient in need of such treatment, comprising:

administering an effective amount of the compound according to claim 1.

12. (Currently Amended) A method of treating a disorder which is responsive to ~~activating~~ activation of a cannibinoid CB1 receptor ~~in a patient in need thereof~~ ,wherein the disorder is selected from the group consisting of multiple sclerosis, spasticity, inflammation, glaucoma, nausea, emesis, loss of appetite, sleep disturbances, respiratory disorders, allergies, epilepsy,

migraine, cardiovascular disorders, neurodegenerative disorders, anxiety, traumatic brain injury and stroke, the method comprising:

administering to a patient an effective amount of the compound according to claim 1.